Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

Subscribe To Our Latest Investor News

News Highlights
April 6, 2021
Not intended for U.S. and UK Media

Bayer to present new clinical data at AACR Annual Meeting 2021

READ MORE
March 23, 2021
Not intended for U.S. and UK Media

Bayer receives approval for Vitrakvi™ in Japan

READ MORE
March 12, 2021

Elections at the Annual Stockholders' Meeting on April 27, 2021

Read more
March 10, 2021
CMD 2021:

Bayer expects dynamic growth with higher profitability in the coming years...

READ MORE
AD HOC

Discover Bayer’s Latest Ad Hoc Releases

READ MORE
Explore All
1 - 10of about 612 News
1 - 10of about 612 News
April 06, 2021
Not intended for U.S. and UK Media
Bayer to present new clinical data in indolent non-Hodgkin’s Lymphoma and additional research on its oncology portfolio at AACR Annual Meeting 2021
READ MORE
March 23, 2021
Not intended for U.S. and UK Media
Bayer receives approval for Vitrakvi™ in Japan
READ MORE
March 12, 2021
Elections at the Annual Stockholders' Meeting on April 27, 2021:
Bayer to further strengthen expertise and international profile of its Supervisory Board
READ MORE
March 10, 2021
Capital Markets Day 2021:
Bayer expects dynamic growth with higher profitability in the coming years and is accelerating its transformation
READ MORE
February 25, 2021
Fiscal 2020:
Bayer delivers robust performance despite pandemic – foundation laid for future growth
READ MORE
February 24, 2021
Bayer to Divest Environmental Science Professional Business and Further Strengthen Leadership Team of Crop Science Division
READ MORE
February 09, 2021
Not intended for U.S. and UK Media
Bayer submits finerenone for marketing authorization in China for the treatment of chronic kidney disease in type 2 diabetes
READ MORE
February 08, 2021
Not intended for U.S. and UK Media
Bayer and Orion expand development program for darolutamide in prostate cancer
READ MORE
February 08, 2021
Not intended for U.S. and UK Media
New data presented at 2021 ASCO GU Cancers Symposium add to robustness of the overall survival benefit and favorable safety profile for Nubeqa™
READ MORE
February 03, 2021
Not intended for U.S. and UK Media
Bayer receives approval for Nubeqa™ in China for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC)
READ MORE
1 - 10of about 612 News
1 - 10of about 612 News